Sign In
Buy WGS
$53.02
-0.110 (-0.207%)
At Close: Jun 03, 2026
GeneDx Holdings Corp. (WGS) Q4 Earnings and Revenues Beat Estimates
11:35am, Monday, 23'rd Feb 2026
GeneDx Holdings Corp. (WGS) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.7 per share a year ago.
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the fourth quarter and full year of 2025.
GeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026
06:30am, Monday, 23'rd Feb 2026
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the fourth quarter and full year of 2025.
TIME Names GeneDx CEO Katherine Stueland to the 2026 TIME100 Health List of the World's Most Influential Leaders in Health
09:05am, Wednesday, 11'th Feb 2026
GAITHERSBURG, Md.--(BUSINESS WIRE)--TIME Names GeneDx CEO Katherine Stueland to the 2026 TIME100 Health List.
CanSinoBIO at WGS 2026: Accelerating Global Access to Innovative Vaccines
08:03am, Monday, 09'th Feb 2026
DUBAI, Feb. 9, 2026 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO"; SSE: 688185, HKEX: 06185) has been invited to share the practices of innovative vaccine at the World Government Summit 2026 (W
Polen 5Perspectives Small Growth Portfolio Performance & Attribution
01:50am, Thursday, 05'th Feb 2026
The Portfolio returned -1.3% gross and -1.5% net compared to the 1.2% return of the Russell 2000 Growth Index. Bloom Energy announced better than expected results with added optimism from a $5B partne
Halper Sadeh LLC Encourages GeneDx Holdings Corp. Shareholders to Contact the Firm to Discuss Their Rights
11:24am, Thursday, 15'th Jan 2026
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of GeneDx Holdings Corp. (NASDAQ: WGS) breached their fiduciary duties
GeneDx Holdings Corp. (WGS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
08:15pm, Wednesday, 14'th Jan 2026
GeneDx Holdings Corp. (WGS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
GeneDx: Fundamentals Intact Though Q4 Results Pause Near Term Momentum
10:21am, Wednesday, 14'th Jan 2026
GeneDx Holdings Corp. is positioned as a leader in advanced exome and genome diagnostics, leveraging its expanding rare disease dataset. Fourth quarter preliminary results met guidance but did not exc
Why is GeneDx stock crashing on Monday?
03:03pm, Monday, 12'th Jan 2026
GeneDx stock (NASDAQ: WGS) plunged 14% on Monday after the genomics testing company released preliminary full-year 2025 results that met expectations. But the company unveiled 2026 guidance that inves
GeneDx Partners With Komodo Health to Advance Rare Disease Research
11:02am, Monday, 12'th Jan 2026
WGS collaborates with Komodo Health to link genomic data with real-world insights, expanding data monetization and strengthening its role in rare disease research.
GeneDx Announces Preliminary 2025 Financial Results and Provides 2026 Guidance
07:30am, Monday, 12'th Jan 2026
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx reported high growth and profitability in preliminary results for the fourth quarter and full year of 2025 and issued 2026 guidance.
GeneDx and Komodo Health Partner to Build the World's Most Complete Longitudinal Rare Disease Dataset
08:30am, Thursday, 08'th Jan 2026
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx and Komodo Health Partner to Build the World's Most Complete Longitudinal Rare Disease Dataset.
GeneDx Announces GenomeDx Prenatal™, Expanding Industry-Leading Genomic Diagnosis Into Prenatal Care
08:30am, Wednesday, 07'th Jan 2026
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx announced GenomeDx Prenatal™, a whole genome sequencing test that delivers fast, comprehensive insights when fetal anomalies are identified.
GeneDx Appoints Dr. Linda Genen as Chief Medical Officer to Accelerate the Future of Genomic-First Care
08:30am, Tuesday, 06'th Jan 2026
GAITHERSBURG, Md.--(BUSINESS WIRE)--Dr. Linda Genen named CMO to further strengthen GeneDx's commitment to delivering earlier answers and better outcomes through genomic insights.
